📰 Recode Therapeutics News
Page 6 - Recode Therapeutics News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recode Therapeutics. Real-time updates on events, politics, business and more.
February 10, 2022
/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global mRNA Manufacturing and Synthesis Services Market–...
February 10, 2022
JERSEY CITY, N.J., Feb. 10, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on "Global mRNA Manufacturing and Synthesis Services Market-
January 3, 2022
In April of this year, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market. In this post we provide a 2021 year in review update on mRNA...
December 9, 2021
/PRNewswire/ -- The "Trikafta Patent, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.coms offering. Global Trikafta market...
December 9, 2021
/PRNewswire/ -- The "Trikafta Patent, Sales & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.coms offering. Global Trikafta market...
November 4, 2021
Plus Smoothie King CEO launches new Asian concept; Rosewood Property Company and Champion Partners started construction on South Dallas industrial; and more.
November 3, 2021
Plus: BioLabs announces two inaugural tenants and outlines future plans; Park Place Dealerships to give away $100,000 to local nonprofits; and more.
October 22, 2021
ReCode Therapeutics closed an $80 million Series B round of financing that included Pfizer and Sanofi as investors. The startup’s technology uses lipid nanoparticles to deliver genetic medicines, and its two lead programs are for rare lung disorders.
October 21, 2021
ReCode Therapeutics is back with its second $80 million financing round, this time a series B from Pfizer, Sanofi and VC shops, to bring its lead programs into human trials. Up first are cystic fibrosis and primary ciliary dyskinesia, another lung disease.
May 11, 2021
Here, in our final post, we provide an analysis of the current landscape and offer conclusions. Moderna, BioNTech and CureVac –Leading Pioneers The three largest and best-positioned players in the mRNA space are currently Moderna, BioNTech and CureVac, each having very large patent estates, 11-figure market caps, double-digit candidates in their pipelines, years of development work and accumulated know-how under their belts, and key licenses and other strategic alliances in place for the manu...